Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

References

• RedfieldMMHeart Failure with preserved ejection fractionN Engl J Med2016375191868187727959663
   PubMed Web of Science ®Google Scholar
• FonarowGCStoughWGAbrahamWTCharacteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF RegistryJ Am Coll Cardiol20075087687717707182
   PubMed Web of Science ®Google Scholar
• BraunwaldEThe war against heart failure: the Lancet lectureLancet2015385997081282425467564
   PubMed Web of Science ®Google Scholar
• MozaffarianDBenjaminEJGoASHeart disease and stroke statistics-2016 update: a report from the American Heart AssociationCirculation2016133438360
   PubMed Web of Science ®Google Scholar
• GheorghiadeMPangPSAcute heart failure syndromesJ Am Coll Cardiol200953755757319215829
   PubMed Web of Science ®Google Scholar
• RudigerAHarjolaVPMullerAAcute heart failure: clinical presentation, one-year mortality and prognostic factorsEur J Heart Fail20057466267015921809
   PubMed Web of Science ®Google Scholar
• FonarowGCAbrahamWTAlbertNMAssociation between performance measures and clinical outcomes for patients hospitalized with heart failureJAMA20072971617017200476
   PubMed Web of Science ®Google Scholar
• RogerVLEpidemiology of heart failureCirc Res2013113664665923989710
   PubMed Web of Science ®Google Scholar
• McMurrayJJPackerMDesaiASAngiotensin-neprilysin inhibition versus enalapril in heart failureN Engl J Med201437111993100425176015
   PubMed Web of Science ®Google Scholar
• YandrapalliSAronowWSMondalPThe evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartanArch Med Sci20171351207121628883863
   PubMed Web of Science ®Google Scholar
• YancyCWJessupMBozkurtB2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of AmericaCirculation20171366e137e16128455343
   PubMed Web of Science ®Google Scholar
• MoeGWEzekowitzJAO’MearaEThe 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implicationsCan J Cardiol201531131625532421
   PubMed Web of Science ®Google Scholar
• PonikowskiPVoorsAAAnkerSD2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Eur J Heart Fail201618889197527207191
   PubMed Web of Science ®Google Scholar
• GuJNoeAChandraPPharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor – neprilysin inhibitor (ARNi)J Clin Pharmacol201050440141419934029
   PubMed Web of Science ®Google Scholar
• VardenyOMillerRSolomonSDCombined neprilysin and renin-angiotensin system inhibition for the treatment of heart failureJACC Heart Fail20142666367025306450
   PubMed Web of Science ®Google Scholar
• YandrapalliSAronowWSMondalPLimitations of sacubitril/valsartan in the management of heart failureAm J Ther2017242234239
   PubMed Web of Science ®Google Scholar
• PackerMMcMurrayJJDesaiASAngiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failureCirculation20151311546125403646
   PubMed Web of Science ®Google Scholar
• McMurrayJPackerMDesaiASA putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failureEur Heart J201536743443925416329
   PubMed Web of Science ®Google Scholar
• FDA news release: FDA approves new drug to treat heart failureU.S. Food and Drug Administration2015 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htmAccessed June 12, 2017
   Google Scholar
• Summary of the Risk Management Plan (RMP) for Entresto (Sacubitril/Valsartan)EMA2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/004062/WC500194315.pdfAccessed June 20, 2017
   Google Scholar
• VinereanuDSacubitril-valsartan for heart failure: from devil’s advocate to evidence-based medicineAm J Ther2017242109110
   Web of Science ®Google Scholar
• DesaiASSolomonSClaggettBFactors associated with non-completion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF TrialCirc Heart Fail201696002735
   Web of Science ®Google Scholar
• FonarowGCStoughWGAbrahamWTCharacteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF RegistryJ Am Coll Cardiol200750876877717707182
   PubMed Web of Science ®Google Scholar
• YancyCWLopatinMStevensonLWClinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) DatabaseJ Am Coll Cardiol2006471768416386668
   PubMed Web of Science ®Google Scholar
• JhundPSFuMBayramEEfficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HFEur Heart J2015362576258426231885
   PubMed Web of Science ®Google Scholar
• NovartisStudy of efficacy and safety of LCZ696 in Japanese patients with chronic heart failure and reduced ejection fraction (PARALLEL-HF) Available from: https://clinicaltrials.gov/ct2/show/NCT02468232. NLM identifier: NCT02468232Accessed August 10, 2017
   Google Scholar
• KristensenSLMartinezFJhundPSGeographic variations in the PARADIGM-HF heart failure trialEur Heart J201637413167317427354044
   PubMed Web of Science ®Google Scholar
• NovartisEfficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF) Available from: http://clinicaltrials.gov/ct2/show/NCT01920711. NLM identifier: NCT01920711Accessed June 11, 2017
   Google Scholar
• NovartisA randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF Patients (PARALLAX) Available from: http://clinicaltrials.gov/ct2/show/NCT03066804. NLM identifier: NCT03066804Accessed June 10, 2017
   Google Scholar
• SimpsonJJhundPSRouleauJEffect of sacubitril/valsartan compared with enalapril, according to etiology in PARADIGM-HFAbstract presented at: American College of Cardiology Scientific SessionsMarch 2017Washington, DC
   Google Scholar
• SolomonSPackerMZileMThe angiotensin receptor neprilysin inhibitor LCZ696 is effective across the spectrum of ejection fraction in heart failure with reduced ejection fractionJ Card Fail2015218S45S46
   Web of Science ®Google Scholar
• DesaiASMcMurrayJJPackerMEffect of the angiotensin receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patientsEur Heart J201536301990199726022006
   PubMed Web of Science ®Google Scholar
• RiddellEVaderJMPotential expanded indications for neprilysin inhibitorsCurr Heart Fail Rep201714213414528281174
   PubMedGoogle Scholar
• JongPYusufSRousseauMFEffect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up studyLancet200336193721843184812788569
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med1992327106696771386652
   PubMed Web of Science ®Google Scholar
• DargieHJEffect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trialLancet200135792661385139011356434
   PubMed Web of Science ®Google Scholar
• SolomonSDClaggettBPackerMEfficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trialJACC Heart Fail201641081682227395349
   PubMed Web of Science ®Google Scholar
• NovartisComparison Of sacubitril/valsartan enalapril on effect on ntpRo-bnp in patients stabilized from an acute heart failure episode (PIONEER-HF) Available from: http://clinicaltrials.gov/ct2/show/NCT02554890. NLM identifier: NCT02554890Accessed June 10, 2017
   Google Scholar
• NovartisComparison of pre- and post-discharge Initiation of LCZ696 Therapy in HFrEF patients after an acute decompensation event (TRANSITION) Available from: http://clinicaltrials.gov/ct2/show/NCT02661217. NLM identifier: NCT02661217Accessed June 9, 2017
   Google Scholar
• NovartisProspective ARNI vs ACE inhibitor trial to determine superiority in reducing heart failure events after MI (PARADISE-MI) Available from: http://clinicaltrials.gov/ct2/show/NCT02924727. NLM identifier: NCT02924727Accessed June 9, 2017
   Google Scholar
• MaggioniAPAnkerSDDahlströmUAre hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registryEur J Heart Fail201315101173118423978433
   PubMed Web of Science ®Google Scholar
• NovartisUK Heart and Renal Protection (UK HARP-III) Available from: http://www.isrctn.com/ISRCTN11958993. NLM identifier: ISRCTN11958993Accessed June 10, 2017
   Google Scholar
• DesaiASVardenyOClaggettBReduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trialJAMA Cardiol201721798527842179
   PubMed Web of Science ®Google Scholar
• KristensenSLPreissDJhundPSRisk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trialCirc Heart Fail201691e00256026754626
   PubMed Web of Science ®Google Scholar
• SeferovicJClaggettBSeidelmannSEffect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialLancet Diabetes Endocrinol20175533334028330649
   PubMed Web of Science ®Google Scholar
• ParikhKSLippmannSJGreinerMScope of sacubitril/valsartan eligibility after heart failure hospitalization: findings from the GWTG-HF Registry (Get With The Guidelines-Heart Failure)Circulation2017135212077208028533321
   PubMed Web of Science ®Google Scholar
• PerezALKittipibulVTangWHWPatients not meeting PARADIGM-HF enrollment criteria are eligible for sacubitril/valsartan on the basis of FDA approval: the need to close the gapJACC Heart Fail20175646046328571599
   PubMed Web of Science ®Google Scholar
• SimpsonJBensonLJhundPSAbstract 19155: “real world” eligibility for sacubitril/valsartan in unselected heart failure patients: data from the Swedish heart failure registryCirculation2016134A19155
   Web of Science ®Google Scholar
• PellicoriPUrbinatiAShahPWhat proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?Eur J Heart Fail201719676877828244205
   PubMed Web of Science ®Google Scholar
• ZeymerUHochadelMAngermannCRepresentativeness of the PARADIGM heart failure population in real lifePresented at: American College of Cardiology Scientific SessionsMarch 2017Washington, DC
   Google Scholar